02609 佰澤醫療
BAYZED HEALTH
BAYZED HEALTH
| Register Close | 2025/06/18 IPO Closing in 4 Days |
| Listing Date | 2025/06/23 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Bayzed Health Group Inc is an oncology healthcare group that principally engages in the investment in, and provision of, medical and healthcare related services in the PRC. The Group is a service provider in the field of full-cycle oncology healthcare services, and screening, diagnosis, treatment and rehabilitation are core services it provided in its full-cycle oncology healthcare services system.
--
According to the report, as of December 31, 2023, the Group ranked the fourth among all private oncology healthcare groups in the PRC in 2023 with corresponding market share of 0.6% in terms of oncology revenue of self-owned hospitals; ranked the first among all private oncology healthcare groups in the PRC in terms of the number of screening and early detection of cancer centers; and ranked the first among all private oncology healthcare groups in the PRC in terms of the number of gastrointestinal endoscopy cases.
--
The Group operated and managed a network of eight hospitals in Beijing, Tianjin, Shanxi Province, Anhui Province and Henan Province with strategic focus on provision of full-cycle oncology healthcare services, through its direct ownership in the equity interest in six private for-profit hospitals and management over two private not-for-profit hospitals.
--
The Group generated revenue primarily from its hospital business, comprising inpatient services, outpatient services and others. The Group’s customers primarily fall into three categories: patients and/or customers that received healthcare services at its self-owned hospitals; Managed Hospital and Health Service Center; and wholesale customers and retail customers.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 600 |
GLOBAL OFFERING
| No. of Offer Shares | 133.11M shares |
| No. of International Offer Shares | 119.79M shares |
| No. of HK Offer Shares | 13.31M shares |
| Offer Price | $4.22 - $6.75 |
| Stock Code | 2609 |
| Sponsor(s) | CMB International Capital Limited |
| Underwriter(s) | CMB International Capital Limited, Futu Securities International (Hong Kong) Limited |
TIME TABLE
| Application Period | Jun 13 (Fri) - noon, Jun 18 (Wed) |
| Price Determination Date | Jun 19 (Thu) |
| Result Announcement Date | On or before Jun 20 (Fri) |
| Result Announcement Date | On or before Jun 20 (Fri) |
| Result Announcement Date | On or before Jun 23 (Mon) |
| Dealings in Shares commence on | Jun 23, 2025. (Mon) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $4.22 - $6.75 |
| Capitalization | 5.56B - 8.90B |
| NAV / share ($) | $0.59 - $0.84 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 5.49, the net proceeds raised would be HKD 623.60M, of which |
| 35.7% : Strengthen full-cycle oncology healthcare services |
| 30.6% : Acquire hospitals when appropriate opportunities arise |
| 15.3% : Expand hospital management business |
| 10.2% : Upgrade IT infrastructure and systems |
| 8.1% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).